MoonLake Immunotherapeutics
MLTXNext catalyst
Sonelokimab
Hidradenitis Suppurativa
Get an email about MLTX's next catalysts
Track MoonLake Immunotherapeutics (MLTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Sonelokimab Phase 3 Est. Readout (IZAR-2)
Estimated primary completion for Sonelokimab trial (NCT06641089) in Arthritis, Psoriatic. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Sonelokimab
Hidradenitis Suppurativa
Risankizumab
Arthritis, Psoriatic
Sonelokimab (M1095)
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sonelokimab | Phase 3 | Hidradenitis Suppurativa | - | - |
Risankizumab | Phase 3 | Arthritis, Psoriatic | - | - |
Sonelokimab (M1095) | Phase 2 | Hidradenitis Suppurativa | - | - |
Frequently asked questions
What is in MoonLake Immunotherapeutics's drug pipeline?β
CatalystAlert tracks 3 drug candidates in MoonLake Immunotherapeutics's (MLTX) pipeline across Phase 3, Phase 2. Its lead program is Sonelokimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MoonLake Immunotherapeutics's next FDA catalyst?β
MoonLake Immunotherapeutics's (MLTX) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MLTX biotech catalysts?β
Add MLTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MoonLake Immunotherapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
